Effectiveness of cenobamate and vagus nerve stimulation (VNS) highlighted at recent EAN congress At the recent 10th Congress of the European Academy of Neurology (EAN), two investigator-led ePresentation sessions on epilepsy outlined the effectiveness of a combination of anti-seizure medication (ASM) cenobamate and vagus nerve stimulation (VNS) in managing drug-resistant epilepsy (DRE). The combination therapy…
Data challenges migraine treatment pauses
New AJOVY® (fremanezumab) migraine prevention data presented at the EAN July 1, 2024: Teva Pharmaceutical Industries Ltd announced new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some…
Kisunla (donanemab) gains full FDA approval
Lilly’s Alzheimer’s drug is a challenger for Biogen and Eisai’s Leqembi July 2, 2024: Eli Lilly’s anti-amyloid therapy donanemab for Alzheimer’s disease was rejected for accelerated approval last year, but the FDA has now given it full approval. The FDA has cleared donanemab-abzt, branded as Kisunla, to treat adults with early symptomatic Alzheimer’s disease, including people…
CE Mark for Image Guided Programming Software for Deep Brain Stimulation
Boston’s Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions Boston Scientific Corporation has obtained a CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology, which when used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) Systems, can provide…
King’s Parkinson’s Charitable Fund launches
Twenty years ago, Professor K Ray Chaudhuri and colleagues wrote in ACNR about the often neglected non-motor symptoms of Parkinson’s which impact so much on a patient’s quality of life – symptoms such as pain, poor sleep, depression, anxiety, sexual dysfunction and autonomic problems. Two decades on, the newly launched King’s Parkinson’s Charitable Fund aims…
How can scientists model the human brain?
bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…
WFNR Franz Gerstenbrand Award 2024 Winner
Dr Christian Endisch, a physician with a neurology residency at the department of Neurology and Experimental Neurology Charité Universitätsmedizin in Berlin, Germany, is the winner of the 2024 World Federation of Neurorehabilitation (WFNR) Franz Gerstenbrand Award. Announced this month at the 13th World Congress for Neurorehabilitation in Vancouver, Canada, Dr Endisch said: “I’m delighted to…
Urgent findings from head-CT scans prioritised by AI at NHS Greater Glasgow and Clyde
First of four NHS sites roll out head-CT AI to highlight critical head injury scans A new multi-NHS site initiative went live in April, aiming to improve radiology report turnaround times for non-contrast CT head scans by creating prioritised reporting worklists of critical findings. This will allow Emergency Department (ED) clinicians at the Queen Elizabeth…
Trofinetide for Rett Syndrome – new drug submission in Canada
23 April 2024: Acadia Pharmaceuticals Inc has announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and…
